BioSpace News Archive

Kleiner Device Labs today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) market clearance for its KG™2 Surge™ flow-thru interbody system.

Codagenix Inc. today announced that their novel intranasal COVI-VAC vaccine has demonstrated promising safety and immunogenicity results in their Phase 1 dose escalation trial in healthy adults.

DJO, a subsidiary of Colfax Corporation and a leading global provider of medical technologies to get and keep people moving, announced the launch of the MedShape® DynaNail Hybrid™ Fusion System.

Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of Louis J. Denis, M.D., as Chief Medical Officer. Dr. Denis brings more than 25 years of clinical development and oncology expertise to Verastem.

Credence MedSystems, Inc. announced today that it has closed a funding round with gross proceeds of $39.9 million. Sources of funding include strategic investments from Novartis Pharma AG, Molex Ventures LLC as well as additional investors.

XOMA Corporation (NASDAQ: XOMA)’s Chief Executive Officer, Jim Neal, will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on Tuesday, September 28, 2021, at 10:20 AM PT.

Vivos Therapeutics, Inc. today announced that Vivos’ Chairman and Chief Executive Officer, Kirk Huntsman, and Vivos’ Chief Financial Officer, Brad Amman, will be presenting at the online Benzinga Healthcare Small Cap Conference at 2:20 pm EST on Wednesday, September 29, 2021.

ContraFect Corporation announces that Roger Pomerantz, M.D., President, Chief Executive Officer and Chairman of ContraFect, will participate in a fireside chat at the Cantor Global Virtual Healthcare Conference, which is being held from September 27 – 30, 2021.

Model Medicines’ CHEMprint™ AI/ML drug discovery platform discovered MDL-001 and identified that the drug was expected to inhibit SARS-CoV-2 replication via a broad spectrum antiviral target, indicating that MDL-001 may be effective against a broad array of RNA based viruses and SARS-CoV-2 variants.

Redpin Therapeutics, Inc. (‘Redpin’ or the ‘Company’), a pioneering chemogenetics company developing uniquely controllable gene therapies to address intractable diseases of the nervous system, today announced the grant of four new patents by the US Patent and Trademark Office covering the Company’s proprietary chemogenetics platform.